Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/7907
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Makrides, M. | - |
dc.contributor.author | Crowther, C. | - |
dc.contributor.author | Gibson, R. | - |
dc.contributor.author | Gibson, R. | - |
dc.contributor.author | Skeaff, C. | - |
dc.date.issued | 2003 | - |
dc.identifier.citation | American Journal of Clinical Nutrition, 2003; 78(1):145-153 | - |
dc.identifier.issn | 0002-9165 | - |
dc.identifier.issn | 1938-3207 | - |
dc.identifier.uri | http://hdl.handle.net/2440/7907 | - |
dc.description | © 2003 American Society for Clinical Nutrition | - |
dc.description.abstract | Background: Iron deficiency anemia (IDA) is common in pregnant women, but previous trials aimed at preventing IDA used high-dose iron supplements that are known to cause gastrointestinal side effects. Objective: The objective was to assess the effect on maternal IDA and iron deficiency (ID, without anemia) of supplementing pregnant women with a low dosage (20 mg/d) of iron. Effects on iron status were assessed at the time of delivery and at 6 mo postpartum. Gastrointestinal side effects were assessed at 24 and 36 wk of gestation. Design: This was a randomized, double-blind, placebo-controlled trial of a 20-mg daily iron supplement (ferrous sulfate) given from 20 wk of gestation until delivery. Results: A total of 430 women were enrolled, and 386 (89.7%) completed the follow-up to 6 mo postpartum. At delivery, fewer women from the iron-supplemented group than from the placebo group had IDA [6/198, or 3%, compared with 20/185, or 11%; relative risk (RR): 0.28; 95% CI: 0.12, 0.68; P < 0.005], and fewer women from the iron-supplemented group had ID (65/186, or 35%, compared with 102/176, or 58%; RR: 0.60; 95% CI: 0.48, 0.76; P < 0.001). There was no significant difference in gastrointestinal side effects between groups. At 6 mo postpartum, fewer women from the iron-supplemented group had ID (31/190, or 16%, compared with 51/177, or 29%; RR: 0.57; 95% CI: 0.38, 0.84; P < 0.005). The rate of IDA between the groups did not differ significantly at 6 mo postpartum. Conclusion: Supplementing the diet of women with 20 mg Fe/d from week 20 of pregnancy until delivery is an effective strategy for preventing IDA and ID without side effects. | - |
dc.description.statementofresponsibility | Maria Makrides, Caroline A Crowther, Robert A Gibson, Rosalind S Gibson and C Murray Skeaff | - |
dc.language.iso | en | - |
dc.publisher | Amer Soc Clinical Nutrition | - |
dc.source.uri | http://www.ajcn.org/cgi/content/abstract/78/1/145 | - |
dc.subject | Iron | - |
dc.subject | pregnancy | - |
dc.subject | iron deficiency | - |
dc.subject | randomized controlled trial | - |
dc.title | Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1093/ajcn/78.1.145 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Makrides, M. [0000-0003-3832-541X] | - |
dc.identifier.orcid | Crowther, C. [0000-0002-9079-4451] | - |
dc.identifier.orcid | Gibson, R. [0000-0002-8750-525X] | - |
Appears in Collections: | Aurora harvest Obstetrics and Gynaecology publications Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.